CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
B 细胞血液系统恶性肿瘤 CAR-T 细胞治疗后的复发机制与治疗策略
英文原题：Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies.
查看英文原题
Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在过去的几十年里，免疫治疗已经彻底改变了现代肿瘤内科领域。嵌合抗原受体（CAR）-T细胞疗法在治疗血液系统恶性肿瘤方面具有前景广阔的疗效。抗CD19 CAR-T 细胞是近年来研究最为成熟的CAR-T 细胞，近年来在治疗B细胞急性淋巴细胞白血病（B-ALL）中已达到约90%的完全缓解率。尽管CAR-T 细胞疗法极大地缓解了白血病或淋巴瘤患者的病情，但其中部分患者治疗后仍会复发。因此，本文中我们讨论了可能导致CAR-T 细胞治疗后疾病复发的因素，并总结了克服这些障碍的潜在策略，从而为改进标准治疗方案提供了可能性。
展开英文摘要原文
Over the past few decades, immunotherapy has revolutionized the modern medical oncology field. Chimeric antigen receptor (CAR)-T cell therapy has a promising curative effect in the treatment of hematological malignancies.
Anti-CD19 CAR-T cells are the most mature CAR-T cells recently studied and in recent years it has achieved a complete remission rate of approximately 90% in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Although CAR-T cell therapy has greatly alleviated the disease in patients with leukemia or lymphoma, some of them still relapse after treatment.
Therefore, in this article, we discuss the factors that may contribute to disease relapse following CAR-T cell therapy and summarize potential strategies to overcome these obstacles, thus providing the possibility of improving standard treatment regimens.
论文信息
- 作者
- Xie D、Jin X、Sun R、Zhang M、Wang J、Xiong X、Zhang X、Zhao M
- 单位
- The First Central Clinical College of Tianjin Medical University, Tianjin, China.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Technology in cancer research & treatment2022 Jan-Dec
- 原文标识
- PubMed 35989682 · DOI 10.1177/15330338221118413
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →